LUNG Pulmonx Corp
Q3 2025 10-Q
Filed: Nov 12, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR Pulmonx Corp (LUNG) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 12, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: no newly added or explicitly changed risk factors disclosed this quarter versus 10-K
- • Most material update: net losses $43.6M vs $43.2M prior year YTD, accumulated deficit $511.1M, emphasizing ongoing losses and need for revenue growth
Quarterly Financial SummaryXBRL
Revenue
$22M
▲ +5.5% YoY▼ -9.9% QoQ
Net Income
-$14M
▲ +1.3% YoY▲ +8.0% QoQ
Gross Margin
74.7%
▲ +95bp YoY▲ +255bp QoQ
Operating Margin
-66.9%
▲ +237bp YoY▼ -489bp QoQ
Net Margin
-64.9%
▲ +447bp YoY▼ -132bp QoQ
ROE
-23.2%
Total Assets
$138M
EPS (Diluted)
$-0.34
▲ +5.6% YoY▲ +10.5% QoQ
Operating Cash Flow
-$8M
▼ -12.7% YoY▼ -108.9% QoQ
Source: XBRL data from Pulmonx Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Pulmonx Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.